TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02358681
Drug: Ketorolac, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 0.5 mg/kg, maximum dose 30 mg. To be administered by intravenous route.
Study: NCT02358681
Drug: Placebo, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of equal volume to IV ketorolac, to be administered by intravenous route.
Study: NCT02358681
Drug: Placebo, intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of equal volume to IN ketorolac, to be administered by intranasal route.
Study: NCT00442936
Drug: Placebo to tecagepant 300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match tecagepant 300 mg liquid-filled soft gel capsules
Study: NCT00442936
Drug: Rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: If moderate or severe migraine headache pain continues or recurs 2 hours after dose of study drug, participants are allowed to take an optional second dose of study drug or their own non-study rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\] or opiates), anti-emetics, or zolmitriptan. Triptans other than zolmitriptan and ergot derivatives are prohibited for 24 hours following the last dose of study drug.
Study: NCT01223131
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:aqueous solution for injection~Route of administration: Subcutaneous
Study: NCT01220206
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo capsules daily
Study: NCT01220206
Drug: One POMx capsule daily
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One POMx capsule, one placebo capsule daily
Study: NCT00104689
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01836705
Drug: SAR302503 (TG101348)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:capsule~Route of administration: oral
Study: NCT01836705
Drug: Placebo SAR302503
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:capsule~Route of administration: oral
Study: NCT01836705
Drug: Panolosetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution~Route of administration: intravenous
Study: NCT02048865
Drug: Placebo drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo drug 2.5mg BID for 6 months
Study: NCT00746096
Drug: IKH-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: ethinyl estradiol 0.035mg and norethisterone 1mg
Study: NCT00746096
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for ethinyl estradiol 0.035mg and norethisterone 1mg
Study: NCT04647604
Drug: Omegaven®
Approvals — FDA: no, EMA: no, PMDA: no
Description: A highly refined fish oil in an emulsion for infusion with purified egg phosphatides and glycerol.
Study: NCT03420482
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo capsules filled with glycerol and cocoa powder. These capsules are identical in appearance to FMT capsules.
Study: NCT04626635
Drug: Trifluridine-tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered per protocol
Study: NCT00179400
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This was a randomized placebo-controlled crossover study in which subjects received both agents in random order, separated by a wash-out period. Following 10 or 21 days' intervention, subjects underwent a pancreatic clamp study.
Study: NCT03282838
Drug: Comparator Celebrex® (fed)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator (Celebrex®) administered to fed subjects
Study: NCT05722301
Drug: Testosterone Therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The testosterone pellet implantation will be performed 2 weeks before surgery. The dose is determined by baseline levels of sex hormone binding globulin (SHBG) in the following manner: If SHBG \> 60nmol/L implant 5 Testosterone Compounded 200mg (total 1000mgs testosterone). If SHBG 41-59 nmol/L implant 4 Testosterone Compounded 200mg (total 800mgs testosterone). If SHBG \<40 nmol/L implant 3 Testosterone Compounded 200mg (total 600mgs testosterone).
Study: NCT00249860
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered subcutaneously three times a week for 12 weeks. The placebo responders will continue the study off-treatment after Week 12 up to Week 24
Study: NCT02028754
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 1 drop in the study eye 4 times a day for the 1st week post surgery, 3 times a day for the 2nd week post surgery, 2 times a day for the 3rd week post surgery, and 1 time a day for the 4th week post surgery.
Study: NCT01646307
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00731627
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet a day for up to 21 days
Study: NCT00731627
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin 40mg once a day for a maximum of 21 days
Study: NCT02586129
Drug: YH14755
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20/1500mg, QD
Study: NCT02586129
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20mg, QD
Study: NCT02210715
Drug: Isentress.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 subjects will change from their normal cART treatment to Raltegravir, which will be given at the standard dose of 400 mg p.o. b.i.d. for 24 months.
Study: NCT03943056
Drug: BIIB091
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT03943056
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT01768286
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir (LDV) 90 mg/sofosbuvir (SOF) 400 mg fixed-dose combination (FDC) tablet administered orally once daily
Study: NCT00679666
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drops are given q 3 minutes before (30 minutes) and during the procedure (30 minutes) but without the use of UVA light. No activation of cross linking occurs.
Study: NCT01147523
Drug: Spironolactone/Vitamin E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone, tablets, 25 mg daily plus Vitamin E, capsules, 400 mg daily, for 52 weeks
Study: NCT01611155
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03319420
Drug: LO2A eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate
Study: NCT03319420
Drug: Systane Ultra UD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Ingredients; Polyethylene Glycol Propylene Glycol
Study: NCT04572243
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to lorcaserin oral tablet, administered as oral suspension.
Study: NCT04456530
Drug: Aveed 750 MG in 3 ML IM Injection
Normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in the Testosterone Group will receive two IM Aveed injections 1 month apart.
Study: NCT04321070
Drug: Clindamycin Phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A thin film of investigation product will be applied to the affected areas of the face once daily
Study: NCT04321070
Drug: Clindamycin Phosphate RLD
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A thin film of investigation product will be applied to the affected areas of the face once daily
Study: NCT04321070
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: A thin film of investigation product will be applied to the affected areas of the face once daily
Study: NCT02193425
Drug: F-18FDG
Normalized name: F
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F-Fluorodeoxyglucose (FDG)-PET session to assess the association between functional connectivity (FC) and glucose metabolism in the human brain.
Study: NCT02359331
Drug: Tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02359331
Drug: 7 days tailored therapy Proton Pump Inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03902912
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prednisolone oral 10 mg/day from day one of the subsequent menstrual cycle to day LH 7 of that cycle. Then, the participants will be given a tailing off dose of 5 mg/day for 3 days followed by 2 mg/day for 3 days and then 1 mg/day for 3 days.
Study: NCT01505530
Drug: LY2495655
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) treatment every 14 days while on study. Number of Cycles: until treatment options are exhausted or unacceptable toxicity develops.
Study: NCT01505530
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) treatment every 14 days while on study. Number of Cycles: until treatment options are exhausted or unacceptable toxicity develops.
Study: NCT01505530
Drug: Standard of Care Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care, gemcitabine-based regimen (single-agent gemcitabine or gemcitabine plus erlotinib) or FOLFIRINOX (combination chemotherapy regimen including 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan). The choice of gemcitabine-based regimen or FOLFIRINOX will be determined by the investigator (based on the standard of care used at the treating institution or as directed by local regulatory authorities).
Study: NCT02063295
Drug: ZGN-440 for injectable suspension
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03003338
Drug: OBV/PTV/r and DSV
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBV/PTV/r (12.5 mg/ 75 mg/ 50 mg) in combination with DSV (250 mg): Two tablets of OBV/PTV/r in the morning and one tablet of DSV in the morning and one tablet of DSV in the evening orally with a meal without regard to fat or calorie content.
Study: NCT03003338
Drug: Placebo to match OBV/PTV/r and DSV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match OBV/PTV/r and DSV
Study: NCT01486433
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg (1 tablet) simvastatin once a day
Study: NCT01486433
Drug: acetylsalicylic acid (ASA)
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 81 mg aspirin (1 tablet), once a day, co-administered with simvastatin
Study: NCT01486433
Drug: omefas
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g (4 capsules) Epanova once a day, co-administered with simvastatin and aspirin
Study: NCT00677118
Drug: Cisplatin,fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive radical radiotherapy and cisplatin (40mg/m2 on day 1) weekly during radiotherapy, then receive cisplatin (80mg/m2 on day 1) and fluorouracil (800mg/m2 on Day 1 to 5) every four weeks for three cycles after completion of radiotherapy.
Study: NCT00473551
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/kg intravenously over two hours on Day -6, immediately following Fludarabine.
Study: NCT01023321
Drug: GLPG0555
Approvals — FDA: no, EMA: no, PMDA: no
Description: single ascending doses, oral solution
Study: NCT01023321
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose, oral solution
Study: NCT01023321
Drug: GLPG0555
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple dose, oral solution, 7 or 14 days
Study: NCT01023321
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple dose, oral solution, 7 or 14 days
Study: NCT02605239
Drug: Bleaching teeth
Normalized name: Coptis teeta root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: bleaching teeth with carbamide peroxide 10% for 3 weeks
Study: NCT02393755
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01741974
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic Karinat 500 mg tablet
Study: NCT03757364
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate in the treatment of distal interphalangeal joint extensor tendon enthesopathy in patients with nail psoriasis
Study: NCT00876200
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.~Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more.
Study: NCT01481597
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 2.5 mg/kg, 5 mg/kg and 7.5mg/kg of deuteporfin (single dose)
Study: NCT02449252
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients in both arms will be given cyclophosphamide chemotherapy.
Study: NCT03818945
Drug: shofu PRG barrier coat
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trilaminar structure which forms a type of stable glass ionomer allowing ion release and recharge, while protecting the glass core from the damaging effects of moisture, greatly improving long-term durability.(Na, BO3, Al, SiO3, F,Sr)
Study: NCT01255475
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo
Study: NCT02521207
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02449252
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients in both arms will be given cyclophosphamide chemotherapy.
Study: NCT00780832
Drug: Anticholinergic medication
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detrol LA 4mg. orally, once daily for 30 days
Study: NCT02983708
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02502253
Drug: grape seed polyphenolic extract, resveratrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioactive Dietary Polyphenol Preparation (BDPP) is a combination of two nutraceutical preparations (grape seed polyphenolic extract \[GSE\], and resveratrol) that contain abundant concentrations of polyphenols.
Study: NCT00216437
Drug: Capecitabine (Xeloda)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01625026
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to obeticholic acid
Study: NCT00680121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03473314
Drug: Nitric Oxide gas at 160ppm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitric oxide gas at 160 ppm inhaled three times daily for 50-80 min delivered with air as the carrier via inhalation for a maximum total of 90 days (extended 365 days twice). Total dose of 480 ppm hours per day.
Study: NCT00651560
Drug: ezetimibe (+) simvastatin
Normalized name: ezetimibe / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe 10mg (+) simvastatin 20 mg once daily for 4 weeks of treatment.
Study: NCT03863457
Drug: Fluoroglutamine [18F]F-GLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluate the kinetics and biodistribution of \[18F\]F-GLN in primary and metastatic breast cancer.
Study: NCT04526496
Drug: Placebo, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to FTP-198, oral suspension
Study: NCT01139164
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other malignancies not addressed in A or C
Study: NCT01796197
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01796197
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02265653
Drug: BIIL 284 BS tablet C
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02265653
Drug: BIIL 284 BS tablet D
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00699751
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline 6 IV administrations separated by 4 weeks intervals.
Study: NCT00699751
Drug: Best standard of care (BSoC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best standard of care is regarded as the routine standard of care at each center, for example local EBRT (External Beam Radiation Therapy), corticosteroids, antiandrogens, estrogens (e.g., stilboestrol), estramustine or ketoconazole.
Study: NCT00130364
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimecrolimus vehicle cream (placebo)
Study: NCT02945215
Drug: IBI301
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI301 375mg/㎡
Study: NCT03897088
Drug: PART 1: Double-blind Placebo-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: all eligible subjects will receive either tildrakizumab or placebo
Study: NCT00626548
Drug: ZD4054
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg once daily oral dose
Study: NCT00626548
Drug: Palcebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Plcebo oral tablet once daily
Study: NCT01976182
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: methotrexate 10mg / m² orally once a week, (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take, during 4 months.
Study: NCT01976182
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take, during 4 months.
Study: NCT00048581
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vials, IV, 0mg, One every 2 weeks for first month then every 4 weeks thereafter, 6 months.
Study: NCT01661270
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Concentrate for Solution for infusion; Route of administration: Intravenous
Study: NCT03834519
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT04484428
Drug: K-285
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: 88 subjects are to be assigned to 1 week dosing, four times a day (QID) (Period 1), and 32 are to be assigned to 3 weeks dosing (Period 1 and Period 2) with 16 subjects each in the two times a day (BID) and QID dosing regimens.
Study: NCT01993875
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching liquid placebo, 0 mcg x 2 pumps administered orally twice daily (BID)
Study: NCT01662466
Drug: Testosterone cream (0.5mg per gram)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone cream 2 gms per day applied transdermally to the left wrist to deliver 1.mg daily dose with estimated absorption of 100 ug per day testosterone
Study: NCT01662466
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrier cream without added testosterone in the identical type of pump
Study: NCT03811080
Drug: DWP14012 A mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will receive treatment of DWP14012 A mg, tablet, orally, once daily and DWP14012 B mg placebo-matching tablet, orally, once daily for up to 4 weeks.
Study: NCT03811080
Drug: DWP14012 B mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will receive treatment of DWP14012 B mg, tablet, orally, once daily and DWP14012 A mg placebo-matching tablet, orally, once daily for up to 4 weeks.
Study: NCT03811080
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will receive treatment of DWP14012 A mg placebo-matching tablet, orally, once daily and DWP14012 B mg placebo-matching tablet, orally, once daily for up to 4 weeks.
Study: NCT03125200
Drug: ADCT-502
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Infusion
Study: NCT04534218
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg per os, daily, for 6 months
Study: NCT04534218
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 625mg/m²/orally twice daily continuously for 6 months
Study: NCT00647816
Drug: Inderal® LA Capsules 160 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160mg, single dose fasting
Study: NCT01439893
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: day1\~day10:0.6ug/kg/day,10hours per day for vein infusion
Study: NCT01658943
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01002690
Drug: Etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg/day orally for 10-13 days
Study: NCT02706184
Drug: E. coli Nissle suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive E. coli Nissle suspension
Study: NCT02706184
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04125836
Drug: CAM2029 (octreotide subcutaneous depot)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide subcutaneous depot for monthly injections in acromegaly patients
Study: NCT00274326
Drug: SR121463B
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00681720
Drug: AZD7325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of oral solution or capsule. 3 times per subject.
Study: NCT02929667
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard 6 weeks titration, starting 10 mg per day.